A 32-year-old resident of Presidente Prudente, Brazil, diagnosed with a rare form of lung cancer, is fighting a legal battle for access to a costly medication that could enhance her treatment.
Amanda Messias Oliveira Gutierrez, a 32-year-old woman from Presidente Prudente, Brazil, has been battling a rare form of lung cancer characterized by the ALK+ genetic alteration since June 2024. Although there is a treatment that could significantly improve her condition, the medication, Alecensa, costs nearly R$ 30,000, which is prohibitive for her. Since April 29, 2025, she has been pursuing legal action to gain access to this essential medication, which has been prescribed by her doctor at the Hospital do Amor in Barretos, SP.
This particular type of lung cancer is considered rare, affecting only 1% to 3% of lung cancer cases, as noted by medical experts. It primarily afflicts younger individuals who have no history of smoking, resembling Amanda’s health background. As she continues with her treatment while facing the challenges of obtaining this expensive medication, Amanda emphasizes that her greatest struggle is against time, as her health condition demands urgent intervention. The high cost of the required medication highlights the broader issues of healthcare access and the financial burdens faced by patients in Brazil.
Amanda's situation raises significant ethical questions regarding the availability of life-saving treatments and the role of the legal system in facilitating access to necessary medications for patients in urgent need. This case could have implications for public health policy discussions in Brazil, as it exemplifies the challenges that individuals encounter when navigating the healthcare system and seeking justice for their health rights.
